Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coronavirus Fallout: India’s Paracetamol Exports Hit

SEZ, Advance License Exports Permitted

Executive Summary

India permits medicines placed on a restricted list to be exported from SEZs and under advance licenses, but paracetamol exporters hope for more easing as restrictions begin to hurt. Meanwhile, the government asks industry to ensure four months of stock as it balances medicines security with economic interest.

You may also be interested in...



COVID-19 Lesson: India Earmarks $1.3bn To Reduce Dependence On China

In a bid to ensure long-term medicines security, the Indian government has earmarked $1.32bn to promote domestic production of 53 APIs, including lopinavir and ritonavir currently being evaluated to treat COVID-19 cases, as well as antibiotics, for which India is highly dependent on China.

India COVID-19 Update: Antivirals, Eyes On HCQ-Azithromycin Data

Development work for antivirals such as favipiravir and remdesivir seen as potential treatments for coronavirus is underway in India, with the former’s off-patent status making it more attractive. All eyes are also on data from a French study which highlights the potential of hydroxychloroquine and azithromycin as a COVID-19 treatment.

EMA Quashes Claims That Ibuprofen Worsens Infection From Coronavirus

Breaking News: The European Medicines Agency says there is no evidence that ibuprofen worsens Covid‑19 and that consumers can carry on using the drug as advised by patient information. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141900

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel